Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2021

View Archived Issues

Qurient initiates phase II study of telacebec in moderate COVID-19

Enrollment opens in phase I study of LP-168 in relapsed or refractory B-cell malignancies

RGS10 gene mutations linked to combined immunodeficiency

Allergy Therapeutics reports findings from ex vivo biomarker study of VLP Peanut

FDA clears IND for [225Ac]PSMA I&T for mCRPC

PanTher receives ethics approval to initiate phase I study of PTM-101 in Australia

Merck & Co. identifies new arginase inhibitors

New MAP2K inhibitors discovered at Immuneering Corp.

GB-5001 demonstrates safety in toxicity study in dogs

The University of Washington and the Department of Veterans Affairs patent glycolysis inhibitors

New cyclophilin ligands described by Harvard College

Exosomes conjugated to VEGF antibodies show efficacy in models of choroidal neovascularization

Target engagement, safety seen with anti-TREM-2 monoclonal antibody AL-002 in healthy subjects

GWAS gives clues to menopause, and healthy aging

89Zr-Immuno-PET using bispecific Abeta MAb as promising diagnostic strategy for Alzheimer's disease

Updated results provided for ACI-24 in adults with Down syndrome

Telix initiates first-in-human study of next-generation prostate cancer therapy candidate TLX-592

Noema studies PDE10A inhibitor NOE-105 for Tourette's syndrome in phase IIa

KIR3DL3-HHLA2 pathway could be targeted for cancer immunotherapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...